Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedExternal links to PubMed and U.S. government sites were removed from the page footer. The core study details and page structure remain unchanged.SummaryDifference0.3%

- Check18 days agoChange DetectedThe page now includes new external references, including a PubMed publication (40598566), and links to government sites such as HHS, NIH, NLM, NCBI, and USA.gov. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check40 days agoChange DetectedUpdated system to revision v3.2.0 and added a government operating status notice; removed the previous No Results Posted and v3.1.0 references.SummaryDifference4%

- Check47 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

- Check61 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.